https://intaspharma.com/ 2020-11-23T06:26:00+00:00 1.00 https://intaspharma.com/about-us/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/about-us/overview/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/about-us/awards-accolades/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/operations/global-operations/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/research-and-developement/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/research-and-developement/overview/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/research-and-developement/platform-technologies/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/research-and-developement/biologics-business-unit/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/manufacturing/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/manufacturing/facilities/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/manufacturing/galleries/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/products/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/media/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/contact-us/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/wp-content/uploads/2020/11/THYMOTAS-5th-nov.pdf 2020-11-05T13:35:37+00:00 0.80 https://intaspharma.com/featured-products/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/financials/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/careers/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/csr/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/environment/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/investors-information/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/adverse-event-reporting/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/terms-of-use/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/disclaimer/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/privacy-policy/ 2020-11-23T06:26:00+00:00 0.80 https://intaspharma.com/operations/ 2020-11-23T06:26:00+00:00 0.64 https://intaspharma.com/wp-content/uploads/2020/11/Thymotas_Launch_News_Coverage.pdf 2020-11-12T04:55:38+00:00 0.64 https://intaspharma.com/wp-content/uploads/2020/08/INTAS-Develops-COVID-19-Hyperimmune-Globulin-A-New-Treatment.pdf 2020-08-27T10:40:59+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/07/Romy.pdf 2020-06-29T09:44:03+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/07/Entrepreneur_of_the_Year_2018.pdf 2020-06-29T09:44:01+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/BIOSIMILAR-AWARDS-2018.pdf 2020-06-29T09:42:10+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/07/Intas_Pelgraz_Pegfilgrastim.pdf 2020-06-29T09:44:02+00:00 0.64 https://intaspharma.com/wp-content/uploads/2020/11/INTAS_launches_THYMOTAS.pdf 2020-11-10T08:04:27+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/02/Entrepreneur_of_the_Year_2018.pdf 2020-06-29T09:43:52+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/1-Intas-pharmaceuticals-to-be-the-first-to-launch-pegfilgrastim-biosimilar-in-europe.pdf 2020-06-29T09:41:12+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/2-Intas-Pharmaceuticals-acquires-the-generics-business-of-Actavis-in-the-UK-Ireland.pdf 2020-06-29T09:41:12+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/3-Intas-brings-down-cancer-cost-by-60.pdf 2020-06-29T09:41:13+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/4-Intas-becomes-the-first-indian-company-to-launch-a-biosimilar-in-the-EU.pdf 2020-06-29T09:41:13+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/5-Intas-acquires-hospital-business-in-spain-and-portugal-from-combino-pharm.pdf 2020-06-29T09:41:14+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/6-Intas-launches-Azacitidine-molecule-in-India.pdf 2020-06-29T09:41:14+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/7-Intas-completes-sale-of-ChrysCapitals-stake-to-Temasek.pdf 2020-06-29T09:41:14+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/8-Intas-launches-rituximab.pdf 2020-06-29T09:41:14+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Albucel.pdf 2020-06-29T09:41:20+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Amtas.pdf 2020-06-29T09:41:21+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Bevatas-vail_Insert_AW-QA-1554-02.pdf 2020-06-29T09:42:10+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/CEFTAS.pdf 2020-06-29T09:42:12+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Clavix.pdf 2020-06-29T09:42:14+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Cloba.pdf 2020-06-29T09:42:15+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/DIVAA.pdf 2020-06-29T09:42:21+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/09/Eleftha_Vial_Insert_AW-QA-1863-00.pdf 2020-06-29T09:44:14+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Gabapin-NT.pdf 2020-06-29T09:42:36+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Globucel.pdf 2020-06-29T09:42:39+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/8609882-HIFENAC-P-PIL.pdf 2020-06-29T09:41:15+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Levera.pdf 2020-06-29T09:43:07+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Lipicure.pdf 2020-06-29T09:43:08+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Looz.pdf 2020-06-29T09:43:11+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Mabtas_100__500_Insert_AW-QA-812-04.pdf 2020-06-29T09:43:17+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/RABIUM20_PIL_685284.pdf 2020-06-29T09:43:36+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/09/ROMY-250%C2%B5g-VIAL-Insert_AW-QA-1909-00.pdf 2020-06-29T09:44:19+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Terifrac.pdf 2020-06-29T09:43:38+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Valprol-CR.pdf 2020-06-29T09:43:41+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Veltam.pdf 2020-06-29T09:43:43+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Zenoxa-od.pdf 2020-06-29T09:43:43+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/Zoryl-M.pdf 2020-06-29T09:43:44+00:00 0.64 https://intaspharma.com/wp-content/uploads/2020/05/API-2-Compliance-Report-Nov-19-to-Apr-20.pdf 2020-09-16T05:01:59+00:00 0.64 https://intaspharma.com/wp-content/uploads/2020/05/API-1-Compliance-Report-Nov-19-to-Apr-20.pdf 2020-09-16T05:02:01+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/12/API-2-Compliance-Report-Jun-19-to-Nov-19.pdf 2020-09-16T05:09:34+00:00 0.64 https://intaspharma.com/wp-content/uploads/2019/12/API-1-Compliance-Report-Jun-19-to-Nov-19.pdf 2020-09-16T05:09:38+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Compliance-Report-Dec-17-to-May-181.pdf 2020-06-29T09:42:01+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-Dec-17-to-May-181.pdf 2020-06-29T09:41:53+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Compliance-Report-Dec-17-to-May-181.pdf 2020-06-29T09:41:42+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-Dec-17-to-May-181.pdf 2020-06-29T09:41:31+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-April-20171.pdf 2020-06-29T09:41:27+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-July-20171.pdf 2020-06-29T09:41:38+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-April-Sept-2017-STP1.pdf 2020-06-29T09:41:27+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-10-12-10-171.pdf 2020-06-29T09:41:43+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-April-171.pdf 2020-06-29T09:41:50+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-10-12-10-171.pdf 2020-06-29T09:42:02+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-April-20161-1.pdf 2020-06-29T09:41:25+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-January-20161.pdf 2020-06-29T09:41:31+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-January-20171.pdf 2020-06-29T09:41:35+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-July-20161.pdf 2020-06-29T09:41:36+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-October-20151.pdf 2020-06-29T09:41:40+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-Analysis-Report-October-20161.pdf 2020-06-29T09:41:41+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-7-16-04-161.pdf 2020-06-29T09:41:47+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-8-15-10-161.pdf 2020-06-29T09:41:47+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-9-07-04-171.pdf 2020-06-29T09:41:50+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-April-20161.pdf 2020-06-29T09:41:52+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-January-20161.pdf 2020-06-29T09:41:54+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-January-20171.pdf 2020-06-29T09:41:55+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-July-20161.pdf 2020-06-29T09:41:57+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-October-20151.pdf 2020-06-29T09:42:00+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-Analysis-Report-October-20161.pdf 2020-06-29T09:42:01+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-7-16-04-161.pdf 2020-06-29T09:42:06+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-8-15-10-161.pdf 2020-06-29T09:42:07+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-9-07-04-171.pdf 2020-06-29T09:42:08+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/EC-API-11.pdf 2020-06-29T09:42:23+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/EC-API-21.pdf 2020-06-29T09:42:23+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-11.pdf 2020-06-29T09:41:43+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-21.pdf 2020-06-29T09:41:44+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-31.pdf 2020-06-29T09:41:44+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-41.pdf 2020-06-29T09:41:45+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-51.pdf 2020-06-29T09:41:44+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-CR-61.pdf 2020-06-29T09:41:45+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-analysis-report-apr-141.pdf 2020-06-29T09:41:23+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-analysis-report-jul-141.pdf 2020-06-29T09:41:33+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-analysis-report-oct-141.pdf 2020-06-29T09:41:38+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-analysis-report-jan-151.pdf 2020-06-29T09:41:28+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-1-form-V-2013-141.pdf 2020-06-29T09:41:48+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-11.pdf 2020-06-29T09:42:03+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-21.pdf 2020-06-29T09:42:03+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-31.pdf 2020-06-29T09:42:04+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-41.pdf 2020-06-29T09:42:04+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-51.pdf 2020-06-29T09:42:04+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-CR-61.pdf 2020-06-29T09:42:05+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-analysis-report-apr-141.pdf 2020-06-29T09:41:48+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-analysis-report-july-141.pdf 2020-06-29T09:41:57+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-analysis-report-oct-141.pdf 2020-06-29T09:41:59+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/API-2-analysis-report-jan-151.pdf 2020-06-29T09:41:52+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/DG-set-air-reports-MATODA-apr-jul-151.pdf 2020-06-29T09:42:20+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/csr-policy.pdf 2020-06-29T09:42:17+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/vigil-mechanism-policy.pdf 2020-06-29T09:43:42+00:00 0.64 https://intaspharma.com/suspected-adverse-drug-reaction/ 2020-11-23T06:26:00+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/adverse-event-reporting-form-for-healthcare-professionals.pdf 2020-06-29T09:41:18+00:00 0.64 https://intaspharma.com/product-complaint-reporting-form/ 2020-11-23T06:26:00+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/product-complaint-reporting-form.pdf 2020-06-29T09:43:31+00:00 0.64 https://intaspharma.com/non-healthcare-professionals-suspected-drug-adverse-event/ 2020-11-23T06:26:00+00:00 0.64 https://intaspharma.com/wp-content/uploads/2018/12/adverse-event-reporting-form-for-non-healthcare-professionals.pdf 2020-06-29T09:41:18+00:00 0.64